In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

This 2020 study by Yao et al. evaluated the antiviral efficacy of hydroxychloroquine (HCQ) against SARS-CoV-2 in vitro and proposed optimized dosing regimens using physiologically based pharmacokinetic (PBPK) modeling. HCQ demonstrated greater potency than chloroquine, with an EC50 of 0.72 μM compared to 5.47 μM. The PBPK model suggested that